Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Chondrogenic Differentiation of Defined Equine Mesenchymal Stem Cells Derived from Umbilical Cord Blood for Use in Cartilage Repair Therapy

Desancé M., Contentin R., Bertoni L., Gomez-Leduc T., Branly T., Jacquet S.

Animal Study on Osteoarthritis, Cartilage Damage, published in Int J Mol Sci (2018) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Int J Mol Sci (2018)
Reported sample size
—
Source database
Europe PMC
PMID
29439436
PMCID
PMC5855759
DOI
10.3390/ijms19020537
Citations
36

Abstract (original English)

Cartilage engineering is a new strategy for the treatment of cartilage damage due to osteoarthritis or trauma in humans. Racehorses are exposed to the same type of cartilage damage and the anatomical, cellular, and biochemical properties of their cartilage are comparable to those of human cartilage, making the horse an excellent model for the development of cartilage engineering. Human mesenchymal stem cells (MSCs) differentiated into chondrocytes with chondrogenic factors in a biomaterial appears to be a promising therapeutic approach for direct implantation and cartilage repair. Here, we characterized equine umbilical cord blood-derived MSCs (eUCB-MSCs) and evaluated their potential for chondrocyte differentiation for use in cartilage repair therapy. Our results show that isolated eUCB-MSCs had high proliferative capacity and differentiated easily into osteoblasts and chondrocytes, but not into adipocytes. A three-dimensional (3D) culture approach with the chondrogenic factors BMP-2 and TGF-β1 potentiated chondrogenic differentiation with a significant increase in cartilage-specific markers at the mRNA level ( Col2a1 , Acan , Snorc ) and the protein level (type II and IIB collagen) without an increase in hypertrophic chondrocyte markers ( Col10a1 and Mmp13 ) in normoxia and in hypoxia. However, these chondrogenic factors caused an increase in type I collagen, which can be red

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
CartilageCells, CulturedChondrocytesMesenchymal Stem CellsFetal BloodAnimalsHorsesCollagenRegenerationCell Differentiation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research